SB206,a New Topical Nitric Oxide-Releasing Drug on the Horizon for the Treatment of Molluscum Contagiosum and External Anogenital Warts

Abstract

Keywords

dermatology molluscum contagiosum wart HPV antiviral drug

Get full access to this article

View all access options for this article.

References

Hebert

AA.

Siegfried

EC.

Durham

et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial. J Am Acad Dermatol. 2020;82(4):887-894 doi:10.1016/j.jaad.2019.09.064

http://www.ncbi.nlm.nih.gov/pubmed/31586600

van der Wouden

JC.

van der Sande

Kruithof

et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5(4):CD004767.doi:10.1002/14651858.CD004767.pub4

http://www.ncbi.nlm.nih.gov/pubmed/28513067

Banerjee

NS.

Moore

DW.

Wang

H-K.

Broker

TR.

Chow

. NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions. Antiviral Res. 2019;170:104559 doi:10.1016/j.antiviral.2019.104559

http://www.ncbi.nlm.nih.gov/pubmed/31319090

Netchiporouk

Cohen

. Recognizing and managing eczematous ID reactions to molluscum contagiosum virus in children. Pediatrics. 2012;129(4):e1072-e1075.doi:10.1542/peds.2011-1054

http://www.ncbi.nlm.nih.gov/pubmed/22412023

Tyring

SK.

Rosen

Berman

et al. A phase 2 controlled study of SB206, a topical nitric oxide-releasing drug for extragenital wart treatment. J Drugs Dermatol. 2018;17(10):1100-1105.http://www.ncbi.nlm.nih.gov/pubmed/30365591